• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Aptalis Pharma

edit

Aptalis Pharma (known as Axcan Pharma until May 2011) is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. Aptalis hopes to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers.

Aptalis was acquired by TPG Capital in 2008, and it acquired Eurand in 2010. It changed its name from Axcan Pharma to Aptalis in May 2011.

Recent Milestones

edit

• 
  Aptalis Pharma acquired Eurand for $583M. (12/1/10)
  Posted 12/3/10 at 10:18pm via thepressreleasewire.com
• 
  Aptalis Pharma added Frank Verwiel as President and CEO. (11/1/10)
  Posted 12/3/10 at 10:04pm
• 
  Aptalis Pharma was acquired by TPG Capital for $1.3B. (2/25/08)
  Posted 8/18/11 at 2:51pm via ccnmatthews.com
• 
  Aptalis Pharma added David W. Mims as Executive Vice President and COO.
  Posted 12/3/10 at 10:04pm
• 
  Aptalis Pharma added Jean Louis Anspach as President, International Specialty Pharmaceuticals.
  Posted 5/24/13 at 10:33pm
• 
  Aptalis Pharma added Steve Gannon as Senior Vice President and CFO.
  Posted 12/3/10 at 10:04pm
• 
  Aptalis Pharma added John Fraher as President, .
  Posted 5/24/13 at 10:39pm
• 
  Aptalis Pharma added Robert Becker as Chief Research Officer.
  Posted 5/25/13 at 1:45am
• 
  Aptalis Pharma added Ruth Thieroff-Ekerdt as Chief Medical Officer.
  Posted 5/25/13 at 2:15am

Videos

Screenshots

edit

Sources

1. Axcan Announces Completion of Transaction With TPG Capital (cnrp.ccnmatthews.com) [edit]
2. Eurand to be Acquired by Axcan for $12.00 per Share in Cash (thepressreleasewire.com) [edit]